News
MBX
57.75
+0.37%
0.21
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
Benzinga · 1d ago
Weekly Report: what happened at MBX last week (0921-0925)?
Weekly Report · 2d ago
MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)
Seeking Alpha · 6d ago
Weekly Report: what happened at MBX last week (0914-0918)?
Weekly Report · 09/21 09:43
Weekly Report: what happened at MBX last week (0907-0911)?
Weekly Report · 09/14 09:45
Press Release: MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
Dow Jones · 09/08 12:00
Weekly Report: what happened at MBX last week (0831-0904)?
Weekly Report · 09/07 09:42
MBX Biosciences (MBX) Is Down 7.5% After Starting Phase 3 oPTimize Trial – Has The Bull Case Changed?
Simply Wall St · 09/04 05:35
Weekly Report: what happened at MBX last week (0824-0828)?
Weekly Report · 08/31 09:46
Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term
Seeking Alpha · 08/28 22:00
MBX Biosciences (MBX), Why Is It Getting So Much Attention Now?
Simply Wall St · 08/28 08:26
MBX Biosciences Begins Pivotal Phase 3 Canvuparatide Trial
TipRanks · 08/27 12:58
MBX Biosciences doses first patient in oPTimize clinical trial
TipRanks · 08/27 12:10
MBX Biosciences Announces First Patient Dosed In Pivotal Phase 3 oPTimize Clinical Trial Evaluating Once-Weekly Canvuparatide For Treatment Of Chronic Hypoparathyroidism
Benzinga · 08/27 12:04
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Barchart · 08/27 07:00
Weekly Report: what happened at MBX last week (0817-0821)?
Weekly Report · 08/24 09:46
MBX Biosciences Price Target Announced at $88.00/Share by JP Morgan
Dow Jones · 08/21 19:12
JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target
Benzinga · 08/21 19:01
MBX Biosciences reinstated with an Overweight at JPMorgan
TipRanks · 08/21 10:31
Weekly Report: what happened at MBX last week (0810-0814)?
Weekly Report · 08/17 09:47
More
Webull provides a variety of real-time MBX stock news. You can receive the latest news about MBX Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About MBX
MBX Biosciences, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. It is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets and proven endpoints for regulatory approval. Its pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase III development and an obesity portfolio that includes MBX 4291 in Phase I development and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. Its lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent glucagon-like peptide 1 (GLP-1) / glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug with the goal of potential once-monthly dosing frequency.